HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers

(marketscreener.com) NEW YORK and VIENNA, Austria, Feb. 13, 2023 -- HOOKIPA Pharma Inc. , a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it has achieved a $10 million non-dilutive milestone payment under its collaboration agreement with Roche to develop HB-700, a novel arenaviral immunotherapy...https://www.marketscreener.com/quote/stock/HOOKIPA-PHARMA-INC-57291650/news/HOOKIPA-Achieves-10-Million-Milestone-Payment-in-Development-of-Immunotherapy-for-KRAS-Mutated-Canc-42972081/?utm_medium=RSS&utm_content=20230213